Pelcitoclax is under investigation in clinical trial NCT04210037 (Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/refractory Small Cell Lung Cancer).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.